Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
"HOT PROMO DARI P0KERV1TA untuk para member kami :
* B0nus Referral 20% Seumur Hidup
* Bonus Hariaan Hingga 3juta
* Bonus Bulanan Hadiah Spesial untuk member yang bermain selama 1 bulan penuh
* Bonus Turn0ver 0,5%
* NO ROBOT & ADMIN
* 100% Fair Play Member Vs Member
* Proses Withdraw & Deposit Tercepat
* Customer Service yang baik dan ramah
Contact Us Person :
? LIVECHAT POKERV1TA
? WA: 082312256064
? BBM : D88B0154"